|
|
OXIGENE BEGINS PHASE II NSCLC TRIAL OF ZYBRESTAT WITH CHEMOTHERAPY.
- Article from:
-
Biotech Business
- Article date:
-
May 1, 2008
|
Copyright informationCOPYRIGHT 2008 Worldwide Videotex. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
OXiGENE, Inc., Waltham, Mass., a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced that the company has begun dosing patients in a randomized, double-blinded, controlled Phase II study of its potential first-in-class vascular disrupting agent (VDA), ZYBRESTAT(tm) (fosbretabulin), in combination with the anti-angiogenic drug, bevacizumab, and the chemotherapeutic agents carboplatin and paclitaxel as first-line therapy for patients with Stage IIIb/IV non-small cell lung cancer (NSCLC).
The multi-center study is being conducted in the US and India and is expected to enroll approximately 60 patients at 14 sites. ...